Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
Source : https://www.tandfonline.com/doi/full/10.1080/16078454.2021.2009645
ABSTRACT Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative...
Conclusion: Based on new data and clinical experience, the panel of experts discussed ruxolitinib treatment in Belgian myelofibrosis patients with a focus on dose optimization/monitoring, adverse events, and interruption/rechallenge management.
Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34907183/
1 Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. [email protected]. 2 Department of Haematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 3 Department of Clinical Immunology, Rigshospitalet, University of...
Conclusion: In this first study of c-aAbs in HSCT patients, we demonstrated that high-titre levels of c-aAb may both persist and emerge in patients over the course of HSCT and may be associated with altered immune biomarkers and cell profiles.
Interleukin-2-inducible T-cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34919342/
Regulatory T cells (Tregs) play an important role in controlling autoimmunity and limiting tissue damage and inflammation. IL2-inducible T cell kinase (Itk) is part of the Tec family of tyrosine...
Conclusion: This peptide inhibitor also significantly reduced inflammatory cytokine production in primary GVHD patient samples and mouse T cells without causing cell death or apoptosis. We provide evidence that specifically targeting Itk signaling could be a therapeutic strategy to treat autoimmune disorders.
Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34880598/
1 Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, People's Republic of China. 2 Department of Hematology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,...
Conclusion: Our real-world data from Chinese patients further confirm that ruxolitinib is a safe and effective treatment for SR-GVHD.
Updates in chronic graft-versus-host disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34889364/
Chronic graft-versus-host disease (GVHD) is the leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation. Symptoms and manifestations of chronic GVHD are heterogeneous and pleomorphic, and there...
Conclusion/Relevance: Multi-institutional collaboration and pharmaceutical support in the development of therapies based on sound biologic mechanisms and clinical trials with defined end points and responses have led to several promising agents on the horizon of approval for treatment of chronic GVHD. This article reviews advances in our...